Andreas F Widmer1, Winfried V Kern2, Jan A Roth3, Markus Dettenkofer4, Tim Goetting4, Hartmut Bertz5, Christian Theilacker3,2. 1. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland. andreas.widmer@usb.ch. 2. Division of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, Faculty of Medicine, Albert-Ludwigs-University, Freiburg, Germany. 3. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland. 4. Department of Environmental Health Sciences and Hospital Infection Control, University Hospital and Medical Center, Faculty of Medicine, Albert-Ludwigs-University, Freiburg, Germany. 5. Division of Hematology, Oncology, and Stem Cell Transplantation, Department of Medicine I, University Hospital and Medical Center, Faculty of Medicine, Albert-Ludwigs-University, Freiburg, Germany.
Abstract
PURPOSE: The length of neutropenia has a significant impact on the incidence of bloodstream infection (BSI) in cancer patients, but limited information is available about the pathogen distribution in late BSI. METHODS: Between 2002 and 2014, BSI episodes in patients with neutropenia receiving chemotherapy for hematologic malignancies were prospectively identified by multicenter, active surveillance in Germany, Switzerland and Austria. The incidence of first BSI episodes, their microbiology and time to BSI onset during the first episode of neutropenia of 15,988 patients are described. RESULTS: The incidence rate of BSI episodes was 14.7, 8.7, and 4.7 per 1000 patient-days in the first, second, and third week of neutropenia, respectively. BSI developed after a median of 5 days of neutropenia (interquartile range [IQR] 3-10 days). The medium duration of neutropenia to BSI onset was 4 days in Escherichia coli (IQR 3-7 days), Klebsiella spp. (2-8 days), and Staphylococcus aureus (3-6 days). In contrast, BSI due to Enterococcus faecium occurred after a median of 9 days (IQR 6-14 days; p < 0.001 vs. other BSI). Late onset of BSI (occurring after the first week of neutropenia) was also observed for Stenotrophomonas maltophilia (12 days, IQR 7-17 days; p < 0.001), and non-albicans Candida spp. (13 days, IQR 8-19 days; p < 0.001). CONCLUSIONS: Over the course of neutropenia, the proportion of difficult to treat pathogens such as E. faecium, S. maltophilia, and Candida spp. increased. Among other factors, prior duration of neutropenia may help to guide empiric antimicrobial treatment in febrile neutropenia.
PURPOSE: The length of neutropenia has a significant impact on the incidence of bloodstream infection (BSI) in cancerpatients, but limited information is available about the pathogen distribution in late BSI. METHODS: Between 2002 and 2014, BSI episodes in patients with neutropenia receiving chemotherapy for hematologic malignancies were prospectively identified by multicenter, active surveillance in Germany, Switzerland and Austria. The incidence of first BSI episodes, their microbiology and time to BSI onset during the first episode of neutropenia of 15,988 patients are described. RESULTS: The incidence rate of BSI episodes was 14.7, 8.7, and 4.7 per 1000 patient-days in the first, second, and third week of neutropenia, respectively. BSI developed after a median of 5 days of neutropenia (interquartile range [IQR] 3-10 days). The medium duration of neutropenia to BSI onset was 4 days in Escherichia coli (IQR 3-7 days), Klebsiella spp. (2-8 days), and Staphylococcus aureus (3-6 days). In contrast, BSI due to Enterococcus faecium occurred after a median of 9 days (IQR 6-14 days; p < 0.001 vs. other BSI). Late onset of BSI (occurring after the first week of neutropenia) was also observed for Stenotrophomonas maltophilia (12 days, IQR 7-17 days; p < 0.001), and non-albicans Candida spp. (13 days, IQR 8-19 days; p < 0.001). CONCLUSIONS: Over the course of neutropenia, the proportion of difficult to treat pathogens such as E. faecium, S. maltophilia, and Candida spp. increased. Among other factors, prior duration of neutropenia may help to guide empiric antimicrobial treatment in febrile neutropenia.
Authors: E Meyer; J Beyersmann; H Bertz; S Wenzler-Röttele; R Babikir; M Schumacher; F D Daschner; H Rüden; M Dettenkofer Journal: Bone Marrow Transplant Date: 2007-02 Impact factor: 5.483
Authors: M Dettenkofer; S Wenzler-Röttele; R Babikir; H Bertz; W Ebner; E Meyer; H Rüden; P Gastmeier; F D Daschner Journal: Clin Infect Dis Date: 2005-03-04 Impact factor: 9.079
Authors: N G Almyroudis; A Fuller; A Jakubowski; K Sepkowitz; D Jaffe; T N Small; T E Kiehn; E Pamer; G A Papanicolaou Journal: Transpl Infect Dis Date: 2005-03 Impact factor: 2.228
Authors: Paul A Mann; Paul M McNicholas; Andrew S Chau; Reena Patel; Cara Mendrick; Andrew J Ullmann; Oliver A Cornely; Hernando Patino; Todd A Black Journal: Antimicrob Agents Chemother Date: 2009-09-28 Impact factor: 5.191
Authors: Malgorzata Mikulska; Valerio Del Bono; Anna Maria Raiola; Barbara Bruno; Francesca Gualandi; Domenico Occhini; Carmen di Grazia; Francesco Frassoni; Andrea Bacigalupo; Claudio Viscoli Journal: Biol Blood Marrow Transplant Date: 2009-01 Impact factor: 5.742